Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)

DB10769ApprovedInvestigationalVaccinesInactivated Japanese Encephalitis Virus Vaccine

Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated): Overview.

First approval
Canada, 2013 · United States, 2009 · European Union, 2020
Also known as
Japanese encephalitis vaccine · Japanese encephalitis vaccine IC51 · Japanese encephalitis virus (inactivated)
Code names
IC-51
Brand names
  • Ixiaro

Resolves to

Compound
UNIIDZ854I04ZE
Clinical / RWD
RxNorm1300779

What you can answer from here — as of March 06, 2025

290Drug interactionsStructured to mechanism, not free text
Sign in
21Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
2ContraindicationsEach with its own population and attribute set
Sign in
12Marketed productsAcross 7 countries and 7 labellers
Sign in

Which other approved drugs treat the same conditions as Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated), and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In